Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Xencor, Inc.

< Previous 1 2 Next >
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at the SVB Securities Global Biopharma Conference
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Third Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Appoints Nancy Valente, M.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Second Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports First Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
From Xencor, Inc.
Via Business Wire
Tickers XNCR
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
From Xencor, Inc.
Via Business Wire
Tickers XNCR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.